BioCentury
ARTICLE | Clinical News

Emricasan regulatory update

December 9, 2013 8:00 AM UTC

Conatus said FDA granted Orphan Drug designation to emricasan to delay the progression to cirrhosis and end-stage liver disease in liver transplant recipients with reestablished fibrosis. The pan-casp...